Dinutuximab - CISMeF

Preferred Label : Dinutuximab;

NCIt synonyms : Monoclonal Antibody Ch14 18; Ch 14.18UTC; Dinutuximab Beta;

NCIt related terms : Ch14.18; monoclonal antibody Ch14.18; MOAB Ch14.18;

NCIt definition : A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.;

Alternative definition : NCI-GLOSS: A substance being studied in the treatment of cancer. It binds to a molecule called GD2, which is found in greater than normal amounts on some types of cancer cells. This helps cells of the immune system kill the cancer cells. It is a type of monoclonal antibody.;

UNII : 7SQY4ZUD30;

CAS number : 1363687-32-4;

Drug name : Unituxin; Qarziba;

Molecule name : Ch14.18;

NSC code : 623408;

Codes from synonyms : CDR0000665424; CDR0000665426; CDR0000665425; 161;

Details

Origin ID

C1570;

UMLS CUI

C0281581;

Currated CISMeF NLP mapping
- Dinutuximab [ICD-11 Extension code]
- Dinutuximab [SMS substance]
- Dinutuximab (substance) [SNOMED CT concept]
- dinutuximab [MeSH concept]
- dinutuximab [MeSH Supplementary Concept]
See also inter- (CISMeF)
- Product containing dinutuximab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Dinutuximab (substance) [SNOMED CT concept]
- Product containing dinutuximab (medicinal product) [SNOMED CT concept]
- ch14.18 [MeSH concept]
- dinutuximab [MeSH Supplementary Concept]
- dinutuximab beta [ATC Code]
Validated automatic mappings to BTNT
- Dinutuximab beta [SMS substance]
- ch14.18 [MeSH concept]
- dinutuximab beta [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
- GD2 Binding [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Antibody-Dependent Cellular Cytotoxicity [NCIt concept]
- Complement-Dependent Cytotoxicity [NCIt concept]
- Immunopotentiation [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
- OS Authorized Value Terminology [NCIt concept]
- OS Total Dose Table [NCIt concept]
has_target
- Ganglioside GD2 [NCIt concept]
is_component_of_chemotherapy_regimen
- Dinutuximab/Irinotecan/Temozolomide Regimen [NCIt concept]
- Interleukin-2/Isotretinoin/Monoclonal Antibody Ch14.18 [NCIt concept]
- Interleukin-2/Monoclonal Antibody Ch14.18 [NCIt concept]
- Interleukin-2/Monoclonal Antibody Ch14.18/Monoclonal Antibody R24 [NCIt concept]
- Isotretinoin/Monoclonal antibody Ch14.18 [NCIt concept]
- Isotretinoin/Monoclonal antibody Ch14.18/Sargramostim [NCIt concept]
- Monoclonal antibody Ch14.18/Sargramostim [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients